Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 15 - Drugs for genital or sexual disorders; Contraceptives
Patents for A61P 15 - Drugs for genital or sexual disorders; Contraceptives (55,635)
04/2003
04/15/2003CA2084775C Method of treating human prostatic adenocarcinoma
04/15/2003CA2053208C Hydroxyalkylquinoline ether acids as leukotriene antagonists
04/15/2003CA2048242C 4-amino-4-steroids and their use as 5.alpha.-reductase inhibitors
04/11/2003WO2002032899A1 Novel anticholinergic agents that can be used as medicaments and method for the production thereof
04/11/2003WO2002032898A2 Novel anticholinergics, method for the production thereof and use thereof as medicaments
04/10/2003WO2003029424A2 Novel proteins and nucleic acids encoding same
04/10/2003WO2003029293A2 Modulators of notch ic protease activity for use in immunotherapy
04/10/2003WO2003029268A1 Androstane 17-beta-carboxamides as androgen receptor modulators
04/10/2003WO2003029212A1 Indole derivatives as cox ii inhibitors
04/10/2003WO2003029200A2 Compounds useful as reversible inhibitors of cysteine proteases
04/10/2003WO2003029199A1 Benzene derivatives, process for preparing the same and use thereof
04/10/2003WO2003028735A1 Estrogen/gestagen combination preparation and application thereof
04/10/2003WO2003028732A1 Receptor antagonist
04/10/2003WO2003028730A2 Pharmaceutical combinations of pde-v inhibitors and other agents
04/10/2003WO2003028715A2 Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis
04/10/2003WO2003028600A1 Wipe formulation
04/10/2003WO2003028527A2 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
04/10/2003WO2003011300B1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
04/10/2003WO2003004493A8 Novel compounds, their preparation and use
04/10/2003WO2003002092A3 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
04/10/2003WO2002102394A3 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
04/10/2003WO2002083108A3 Compositions containing cgmp pde inhibitors and local anaesthetic agents for nasal application
04/10/2003WO2002074238A3 Water soluble and palatable complexes
04/10/2003WO2002060423A3 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
04/10/2003WO2002057460A3 Polynucleotides encoding human phosphatases
04/10/2003WO2002040666A3 Fat regulated genes, uses thereof, and compounds for modulating same
04/10/2003WO2002008396A3 Human proteases
04/10/2003US20030069429 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress
04/10/2003US20030069422 Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof
04/10/2003US20030069406 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of blood disorders
04/10/2003US20030069303 Osteoporosis, postmenopause
04/10/2003US20030069287 Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors
04/10/2003US20030069246 Central nervous system disorders; psychological disorders; cardiovascular disorders
04/10/2003US20030069183 Lyophilized HGF preparations
04/10/2003US20030069181 Alternative splice forms of proteins as basis for multiple therapeutic modalities
04/10/2003US20030068378 Mucosal surface-coat-forming film dosage units containing a water-soluble hydrocolloid, an effective dose of a sexual dysfunction active agent and a mucosal adhesion enhancer, wherein mucosal adhesion enhancer is a starch graft copolymer
04/10/2003CA2462075A1 Estrogen/gestagen combination preparation and application thereof
04/10/2003CA2461670A1 Indole derivatives as cox ii inhibitors
04/10/2003CA2461099A1 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
04/10/2003CA2459825A1 Compounds useful as reversible inhibitors of cysteine proteases
04/10/2003CA2458343A1 Pharmaceutical combinations of pde-v inhibitors and other agents
04/10/2003CA2455225A1 Novel proteins and nucleic acids encoding same
04/10/2003CA2430328A1 Receptor antagonist
04/09/2003EP1300468A2 TRNA synthetase
04/09/2003EP1300424A1 Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
04/09/2003EP1299545A2 Drug metabolizing enzymes
04/09/2003EP1299541A2 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses
04/09/2003EP1299536A1 Novel alpha-catenin expressed in heart and testis
04/09/2003EP1299412A2 Protein modification and maintenance molecules
04/09/2003EP1299385A2 Fused cyclic modulators of nuclear hormone receptor function
04/09/2003EP1299363A1 Polymorphic forms/hydrates of n- 4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride
04/09/2003EP1299362A1 Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof
04/09/2003EP1299105A2 Compositions comprising folic acid and zinc for improving male fertility
04/09/2003EP1299092A2 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel
04/09/2003EP1299010A1 Vitamin k and essential fatty acids
04/09/2003EP1150574A4 A natural tea for curing men's impotence and a method for manufacturing the same
04/09/2003EP1003477B1 Therapeutical system for transdermal delivery of levonorgestrel
04/09/2003EP0793492B1 Use of sclareolide for treating disorders characterised by excessive cell proliferation
04/09/2003CN1409765A Prevention of myocarditis, abortion and intrauterine infection associated with procine circovirus 2
04/09/2003CN1409630A Sustainable-release formulations for treating CNS-mediated disorders
04/09/2003CN1408869A Mouse spermotogenous cell differentiation relative gene
04/09/2003CN1408373A Medicine for resisting senility, shrinking vagina, beautifying breast and stregthening male genitals and its production method
04/09/2003CN1408356A Composition of mifepristone semi-solid skeleton preparation
04/09/2003CN1408355A Medicinal composition and medicine kit containing estrin
04/09/2003CN1105116C Thienopyrimidine with PDE V-inhibiting effect
04/09/2003CN1105101C Beta-sultonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
04/09/2003CN1104896C RAR-gamma antagonist ligand or RAR-alpha agonist ligand as apoptosis inhibitor
04/08/2003US6545038 Heterocyclic metalloprotease inhibitors
04/08/2003US6544995 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric G protein
04/08/2003US6544993 Tetrahydrothiopyranphthalazinone derivatives as PDE4 inhibitors
04/08/2003US6544981 Anticoagulants, cardiovascular disorders
04/08/2003US6544970 Administering in a first phase of a progestational agent (levonorgestrel or ethinylestradiol) and in a second phase an antiprogestin that is an indolinone derivative, especially a 3-spiroalkylene derivative
04/08/2003US6544759 Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
04/08/2003US6544740 Measuring protease; calibration; insertion of enbryos
04/08/2003US6544556 Prevents gastrointestinal side effects
04/08/2003CA2123548C Piperazine derivatives
04/08/2003CA2049212C 6-substituted-tetrahydrobenz ¬cd| indoles
04/08/2003CA2048243C 4-amino- 4,6-steroids and their use as 5-.alpha.-reductase inhibitors
04/03/2003WO2003027263A2 Proteins associated with cell growth, differentiation, and death
04/03/2003WO2003027234A2 Small organic molecule regulators of cell proliferation
04/03/2003WO2003027114A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
04/03/2003WO2003027107A1 Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors
04/03/2003WO2003027105A1 Substituted 3-pyridyl thiophenes as c17,20 lyase inhibitors
04/03/2003WO2003027101A1 Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors
04/03/2003WO2003027100A1 Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors
04/03/2003WO2003027096A1 Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
04/03/2003WO2003027095A1 Substituted 3-pyridyl tetrazoles as steroid c17,20 lyase inhibitors
04/03/2003WO2003027094A2 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
04/03/2003WO2003027090A2 Bicyclic heterocycles as rxr ligands
04/03/2003WO2003027085A2 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
04/03/2003WO2003027075A2 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
04/03/2003WO2003027069A1 Preparation and use of pyrrole derivatives for treating obesity
04/03/2003WO2003026681A1 Inactivation of papillomavirus
04/03/2003WO2003026663A1 Process for making substituted pyrazoles
04/03/2003WO2003026659A1 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
04/03/2003WO2003026649A1 Methods of increasing endogenous testosterone levels
04/03/2003WO2003026568A2 Androstanes as androgen receptor modulators
04/03/2003WO2003002530A3 Pyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2002102799A3 Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists
04/03/2003WO2002086078A3 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
1 ... 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 ... 557